首页> 外文期刊>International immunopharmacology >Ligustrazine corrects Th1/Th2 and Treg/Th17 imbalance in a mouse asthma model
【24h】

Ligustrazine corrects Th1/Th2 and Treg/Th17 imbalance in a mouse asthma model

机译:川gust嗪可纠正小鼠哮喘模型中Th1 / Th2和Treg / Th17失衡

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Asthma is an inflammatory disease closely associated with activated T cells in the lung. Imbalances in Th1/Th2 and Treg/Th17 have been found in asthmatic patients. Ligustrazine from the Chinese herb chuanxiong has been used in China in combination with glucocorticoids to treat asthma. Previous studies have proved that ligustrazine can modulate the expression of transcription factors for Th1 (T-bet) and Th2 (Gata-3) in asthma. In the present study, ligustrazine alleviated allergic airway inflammation in a mouse asthmatic model by reducing the influx of eosinophils and neutrophils, which was mediated, at least in part, by the regulation of Th1/Th2 and Treg/Th17 via the re-balance of cytokine profiles and of ratios of transcription factors, T-bet/Gata-3 and Foxp3/RORγt, thus providing new insights into the mechanisms of action for asthma treatment with ligustrazine.
机译:哮喘是一种与肺中活化T细胞紧密相关的炎性疾病。在哮喘患者中发现了Th1 / Th2和Treg / Th17的失衡。来自中国的川xi中的川gust嗪已在中国与糖皮质激素联合用于治疗哮喘。先前的研究证明川li嗪可以调节哮喘患者Th1(T-bet)和Th2(Gata-3)转录因子的表达。在本研究中,川gust嗪通过减少嗜酸性粒细胞和嗜中性粒细胞的流入减轻了小鼠哮喘模型中的过敏性气道炎症,这至少部分地是通过调节T1 / Th2和Treg / Th17的重新平衡来介导的。细胞因子谱以及转录因子,T-bet / Gata-3和Foxp3 /RORγt的比率,从而为川li嗪治疗哮喘的作用机理提供了新见识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号